Jan 22 (Reuters) - Abbott Laboratories ( ABT ) on

Wednesday forecast annual profit in line with Wall Street

estimates, as it expects elevated medtech-related procedures to

boost demand for its devices, including glucose-monitoring

products.

Sales of continuous glucose monitors such as Abbott's

FreeStyle Libre and rivals from DexCom ( DXCM ) have been lifted

by increasing diabetes care awareness, bigger insurance coverage

and preference for devices that do not need finger pricks.

Abbott expects an adjusted profit of $5.05 to $5.25 per

share for 2025, compared with analysts' average profit

expectation of $5.16.

On an adjusted basis, the company reported a quarterly

profit of $1.34 per share, in line with analysts' average

expectations, according to estimates compiled by LSEG.